Aiming at the CDMO business, multinational pharmaceutical companies have "marriages" and sell-offs

【Pharmaceutical Network Industry News】On October 10, the news was officially held
at the signing ceremony of the trademark license of Merck Group of multinational pharmaceutical company Merck Group Trademark License Bio Wisdom Valley (Chengdu) Technology Co.
, Ltd.
and the launching ceremony of Merck's Empowerment Composite Macromolecule CDMO Project.
Through this "marriage", Merck will work with BioWisdom Valley to jointly build a macromolecular composite CDMO public technology service platform project
for biopharmaceutical innovation enterprises and industries in the Sichuan-Chongqing region 。 The project content includes public R&D platform, process development and protein characterization research laboratory, pilot workshop, biomedical research and development, production technology service outsourcing business, which can provide advanced laboratory materials and equipment, cutting-edge technology and services, regulatory policies and quality management knowledge, consulting, training and technical support for biopharmaceutical enterprises at different stages, and promote a number of biomedical projects with independent intellectual property rights to settle in Chengdu
。 CDMO full name is pharmaceutical contract custom R & D and production services, mainly for pharmaceutical companies to provide process research and development and preparation, process optimization, scale-up production and other outsourcing services, in recent years, with the rise of biological drug research and development boom, CDMO industry has also been rapid growth, the market scale continues to expand
.
The industry expects that by 2025, the scale of the domestic CDMO industry will exceed 120 billion yuan, with a compound growth rate of more than 31%.
However, although the CDMO industry has broad prospects, the competition on the track is also very fierce, and some multinational pharmaceutical companies have even made the decision to
"break up" and sell.
Recently, Jiuzhou Pharmaceutical, which acquired Novartis' Suzhou plant in 2019, announced that the Zhongshan Preparation Factory (hereinafter referred to as "Sandoz Zhongshan Pharmaceutical Factory"), a subsidiary of Sandoz (China), was acquired
by Kyushu Pharmaceutical for 185 million yuan.
The company said that after the completion of the acquisition of Sandoz Zhongshan Pharmaceutical Factory, the remaining funds will increase the capital of Sandoz Zhongshan Pharmaceutical Factory for the implementation of the CDMO (Pharmaceutical Commercial Production Outsourcing) preparation transformation and expansion project
of Sandos Zhongshan Pharmaceutical Factory.
It is reported that Sandoz Zhongshan Pharmaceutical Factory is a new subsidiary of Novartis' Sandoz (China), and will integrate the manufacturing assets, production and management teams of the stripped preparations into the new company
.
The industry believes that for acquirers, expanding production through acquisition is a fast way to help pharmaceutical companies improve their own development
more efficiently.
It is reported that in order to accelerate the construction of CDMO production capacity, in 2021, Jiuzhou Pharmaceutical will also acquire 100% of the equity of Taihua Hangzhou under Teva Group for more than 30 million US dollars, further realizing its multi-regional production capacity layout
。 Taihua Hangzhou is a API production plant invested by Teva in China, which has reached international standards in terms of production management mode, quality control system guarantee, green innovation technology, etc.
, production management is carried out in strict accordance with GMP standards, and has passed the CDE, U.
S.
FDA and EU EDQM audits for many times, with an efficient and stable quality system and a world-class environmental protection and safety management system
.
In the first half of 2022, Jiuzhou Pharmaceutical announced the completion of the acquisition of 51% of the equity of Kangchuanji Pharmaceutical to quickly enhance the company's ability to undertake
CDMO preparation research and development 。 Since the beginning of this year, in addition to the frequent acquisitions of Kyushu Pharmaceutical in local pharmaceutical companies, there are also Kanglong Chemical Chemicals' acquisition of Aesica Pharmaceuticals in the United Kingdom and Coventry's API production base in the United States, both of which can provide cGMP API production services from pilot to tonnage commercialization, and have been verified and certified by a number of regulatory agencies, including the US Food and Drug Administration.
It will enhance the company's overall strength in small molecule CDMO and drug safety evaluation.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.